(International Print/Online Journal)

SJIF IMPACT FACTOR: 5.565
PUBMED-National Library of Medicine ID-101739732

ISSN (Print): 2209-2870
ISSN (Online): 2209-2862

International Journal of Medical Science and Current Research (IJMSCR)
Available online at: www.ijmscr.com
Volume 5, Issue 1, Page No: 265-267
January-February 2022

IJMSCR

Recent Advancement In The Treatment Of Hypoparathyroidism

Dr. Kaushika Premchand
G 24 block 8, Neyveli, Neyveli T.S

***Corresponding Author:**
Dr. Kaushika Premchand
G 24 block 8, Neyveli, Neyveli T.S

Type of Publication: Original Research Paper
Conflicts of Interest: Nil

Abstract

Keywords: NIL

Introduction

Hypoparathyroidism is an uncommon hormonal disorder wherein the parathyroid gland's synthesis of parathyroid hormone (PTH) is missing or unusually low. PTH is mainly important for controlling calcium balance in the bloodstream. It also controls phosphorous levels and contributes in the synthesis of vitamin D in its activated state. Sustaining calcium balance demands every one of these processes. Destruction to or ablation of the parathyroid during neck surgery is by far the most common causes of Hypoparathyroidism, responsible for nearly 75 percent of cases.

In contrast to primary hyperparathyroidism, a very common illness characterized by excessive PTH production, its rare counterpart Hypoparathyroidism has received little attention and research until recently. As a result, guidelines for its therapeutic administration have only recently piqued interest and become the focus of concerted consideration.

This assignment is useful to anyone who is interested in Hypoparathyroidism or will become interested in the future. Hypoparathyroidism is summarised, and significant innovations in its treatment are put into context, which should allow us to understand this ailment in the foreseeable.

Causes Of Hypoparathyroidism

1. One of most major reason of Hypoparathyroidism is a surgical error that damages or removes the parathyroid glands.

2. Persons who have the hereditary genetic condition such as DiGeorge syndrome may have undeveloped parathyroid glands that can cause Hypoparathyroidism at later stages of life.

3. Treatment for neck or throat cancer with radiotherapy also accounts for the prevalence of Hypoparathyroidism.

4. Drinking too much alcohol might produce low magnesium levels in the bloodstream leading to problems of Hypoparathyroidism.

Management Of Hypoparathyroidism

Goals Of Management

1. It aids in the prevention of hypocalcemia symptoms.

2. Maintain average or somewhat below average levels of serum calcium. Overshooting the standards tend of calcium levels for the regular populace is typically not recommended.

3. As much as appropriate, keep your serum phosphorus level at or around the normal range.

4. A healthy level of serum magnesium should be maintained.

5. If at all possible, try to maintain original pH balance of your calcium phosphate solution

There are different ways of managing Hypoparathyroidism. Some of the ways are:

1. **Acute management:** When a patient's chronic replacement routine is disrupted due to gastrointestinal disease or another aggravating circumstance, they can develop Hypoparathyroidism and become acutely hypocalcemic.
2. **Calcium Supplements:** Hypoparathyroidism cannot be managed by supplying adequate calcium intake through the diet. It's also worth noting that calcium-rich dairy products include phosphate. A calcium supplement can't be compromised. It's typical for patients to require between 1 and 2 g of supplemental calcium per day, taken in 500 mg dosages. As a result of its high molecular weight, calcium carbonate is a more efficient supplier of calcium. Acid must be present in order for calcium carbonate to be absorbed. This acid might come from the stomach or from a protein-based diet. Hypoparathyroidism isn't immediately affected by research on the long-term cardiovascular risk that come from looking at whether calcium supplementation is hazardous or not. To begin with, the doses required by these patients are often larger than those suggested, averaging >2.5 g/day.
3. **Thiazide diuretics:** People with acute hypercalciuria can be treated with thiazide diuretics. As a secondary effect of thiazide diuretics, magnesium loss and renal potassium depletion are possible. Individuals with inflammatory polyendocrine syndrome type 1 but those with ADH are not allowed to take Bartter syndrome medications.
4. **Parathyroid Hormone:** In the absence of Parathyroid hormone, normal calcium homeostasis cannot be restored at the kidney, the skeleton, or other sites such as the central nervous system, which have been implicated in the unconventional elements of Parathyroid hormone activity. Hence, maintaining levels of parathyroid hormone is important.

Apart from the above mentioned ways to manage Hypoparathyroidism, there are other ways that have taken their way in the present to cure or prevent the disease. The therapy of Hypoparathyroidism is generally based on chronic and conventional methods, however substantial dosages of calcium and vitamin D are indeed routinely utilised.

A lot of studies have showed some other techniques to manage Hypoparathyroidism in patients. The usage of teriparatide (rhPTH[1-34]) in hypoparathyroid individuals has been documented. However, despite the fact that it has not been licensed by the FDA for the management of hypoparathyroidism, clinical trials have demonstrated its effectiveness. Because of the very short time it takes for teriparatide to boost serum calcium levels, individualized dose, such as two times or even three times injections, may be essential.

PTH(1-34) in the form of TransCon PTH, a dormant prodrug that releases active PTH continuously, has the possibility to be a revolutionary therapeutic. Specifically, a rise in bone resorption has been reported with TransCon PTH delivery. Hypoparathyroidism's low bone turnover rate and high bone mineral density can both be alleviated by increasing resorption, even though this could possibly result in a primary hyperparathyroid profile. TransCon PTH is now being tested in a phase II experiment.

The full-length peptide of PTH (1-84) is precisely what is missing in hypoparathyroidism, making it a more appealing prospect for use as a replacement hormone. Taking it once daily is more realistic because of its longer half-life in vivo and in the body compared to PTH (1–34). Nonsurgical hypoparathyroidism was approved by the FDA. A "black box" warning was added by the FDA to the approval of rhPTH (1-84) due to the development of rat osteosarcoma in studies including all forms of PTH. However, no time limit was placed on the use of rhPTH.

Conclusion

A major advancement in the management of Hypoparathyroidism is that of an introduction of PTH (1-84) which can be a useful treatment for Hypoparathyroidism. It is also uncertain how to treat bone disease in chronic hypoparathyroidism, which is thought to exacerbate poor turnover degenerative disease and contribute to high bone density. The use of rhPTH(1–84) hormone treatment has been shown to increase bone turnover, stabilise hip bone mass, and reduce wrist bone density. As a result, it

Volume 5, Issue 1; January-February 2022; Page No 265-267

stabilises bone mass in the hip and lowers bone mass in the wrists.

Apart from this it was seen that the quality of life of the patients have been compromised at greater levels. Hence, managing one's quality of life is an important aspect to keep in mind which would further help to reduce chronic Hypoparathyroidism in patients.

To conclude, though there have been advancements to the treatment of Hypoparathyroidism a lot of researches has investigated that classical treatment techniques such as conventional or chronic management techniques are still used for the management of Hypoparathyroidism.

References

1. Bilezikian JP, Khan A, Potts JT Jr, Brandi ML, Clarke BL, Shoback D, Jüppner H, D'Amour P, Fox J, Rejnmark L, Mosekilde L, Rubin MR, Dempster D, Gafni R, Collins MT, Sliney J, Sanders JJ Bone Miner Res. 2011 Oct; 26(10):2317-37.
2. Brandi ML, Bilezikian JP, Shoback D, et al. Management of hypoparathyroidism: summary statement and guidelines. J Clin Endocrinol Metab. 2016;101(6):2273–2283.
3. Gabbey, A. E. (2020, March 12). Parathyroid hormone (PTH) test. Healthline. Retrieved December 28, 2021, from https://www.healthline.com/health/pth#results
4. Heaney RP, Smith KT, Recker RR, Hinders SM. Meal effects on calcium absorption. Am J Clin Nutr. 1989;49(2):372–376
5. Holten-Andersen L, Pihl S, Rasmussen CE, et al. : Design and Preclinical Development of TransCon PTH, an Investigational Sustained-Release PTH Replacement Therapy for Hypoparathyroidism. *J Bone Miner Res.* 2019;34(11):2075–86. 10.1002/jbmr.3824
6. Lewis JR, Calver J, Zhu K, Flicker L, Prince RL. Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up. J Bone Miner Res. 2011;26(1):35–41. 107.
7. Mannstadt M, Clarke BL, Vokes T, et al. : Efficacy and safety of recombinant human parathyroid hormone (1–84) in hypoparathyroidism (REPLACE): A double-blind, placebo-controlled, randomised, phase 3 study. *Lancet Diabetes Endocrinol.* 2013;1(4):275–83. 10.1016/S2213-8587(13)70106-2
8. Mayo Foundation for Medical Education and Research. (2020, December 2). *Hypoparathyroidism*. Mayo Clinic. Retrieved December 28, 2021, from https://www.mayoclinic.org/diseases-conditions/hypoparathyroidism/symptoms-causes/syc-20355375
9. NHS. (n.d.). NHS choices. Retrieved December 28, 2021, from https://www.nhs.uk/conditions/hypoparathyroidism/
10. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53–58.
11. Sikjaer T, Amstrup AK, Rolighed L, Kjaer SG, Mosekilde L, Rejnmark L. PTH(1-84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment. J Bone Miner Res. 2013;28:2232–2243
12. Winer KK, Yanovski JA, Cutler Jr GB: Synthetic human parathyroid hormone 1–34 vs calcitriol and calcium in the treatment of hypoparathyroidism. *JAMA.* 1996;276(8):631–6. 10.1001/jama.1996.03540080053029
13. Zavatta, G., & Clarke, B. L. (2020). Challenges in the management of chronic hypoparathyroidism. *Endocrine connections*, *9*(10), R229–R240. Advance online publication. https://doi.org/10.1530/EC-20-0366

Volume 5, Issue 1; January-February 2022; Page No 265-267